Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 8:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Arterial Embolism and Thrombosis Clear all
Terminated No phase listed Observational

Comparison of Phase-variance Optical Coherence Tomography and Fluorescein Angiography in Retinovascular Imaging

NCT01717937
View directory record Official record
Conditions
Age-related Macular Degeneration, Diabetic Retinopathy, Hypertensive Retinopathy, Retinal Vein Occlusion, Retinal Artery Occlusion
Interventions
Phase variance optical coherence tomography (PV-OCT)
Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
13 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 3, 2014 · Synced Jun 10, 2026, 8:29 AM EDT
Terminated Phase 3 Interventional

Clopidogrel and the Optimization of Gastrointestinal Events (COGENT-1)

NCT00557921
View directory record Official record
Conditions
Acute Coronary Syndrome, Myocardial Infarction, Coronary Artery Disease, Percutaneous Coronary Intervention
Interventions
CGT-2168 (clopidogrel 75 mg/omeprazole 20 mg) and aspirin, Plavix (clopidogrel 75 mg) and aspirin
Drug
Lead sponsor
Cogentus Pharmaceuticals
Industry
Eligibility
21 Years and older
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
247
States / cities
Alexander City, Alabama • Birmingham, Alabama • Geneva, Alabama + 205 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2009 · Synced Jun 10, 2026, 8:29 AM EDT
Active, not recruiting Not applicable Interventional

Thromboelastography With Platelet Mapping to Guide Antiplatelet Therapy After Lower Extremity Revascularization

NCT07597239
View directory record Official record
Conditions
Thrombosis, Arterial Occlusive Diseases, Thromboelastography (TEG), Peripheral Arterial Disease(PAD), Stent Thrombosis, Platelet Inhibition, PRU(Platelet Reactivity Unit)
Interventions
Aspirin, Clopidogrel, Ticagrelor, Platelet Reactivity Testing, Thromboelastography with Platelet Mapping
Drug · Diagnostic Test
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Jun 10, 2026, 8:29 AM EDT
Terminated Phase 2Phase 3 Interventional

Evaluation of the TriActiv ProGuard System During Carotid Artery Stenting

NCT00395785
View directory record Official record
Conditions
Carotid Stenosis
Interventions
Carotid Stent Implantation, Embolic Protection
Device
Lead sponsor
Kensey Nash Corporation
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
31
States / cities
Birmingham, Alabama • Fairhope, Alabama • Beverly Hills, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2007 · Synced Jun 10, 2026, 8:29 AM EDT
Completed No phase listed Observational

Quantra Determination of Coagulation Parameters in Arterial and Venous Blood

NCT02978872
View directory record Official record
Conditions
Cardiac Surgery
Interventions
Not listed
Lead sponsor
HemoSonics LLC
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 18, 2017 · Synced Jun 10, 2026, 8:29 AM EDT
Completed Phase 3 Interventional Results available

Efficacy And Safety Of Clopidogrel In Neonates /Infants With Systemic To Pulmonary Artery Shunt Palliation

NCT00396877
View directory record Official record
Conditions
Heart Defects, Congenital
Interventions
Clopidogrel (SR25990), placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
Up to 92 Days
Enrollment
906 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 23, 2014 · Synced Jun 10, 2026, 8:29 AM EDT
Recruiting Not applicable Interventional

Pharmacy-led Transitions of Care Intervention to Improve Medication Adherence

NCT06374277
View directory record Official record
Conditions
Diabetes, Hypertension, High Cholesterol/Hyperlipidemia, Coronary Artery Disease, Congestive Heart Failure, Chronic Lung Disease, Chronic Kidney Diseases, Arrythmia, Stroke, Depression, Anxiety, Pulmonary Embolism, Heart Attack
Interventions
Med AAAction intervention
Other
Lead sponsor
University of Tennessee
Other
Eligibility
18 Years and older
Enrollment
388 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
2
States / cities
Knoxville, Tennessee • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Jun 10, 2026, 8:29 AM EDT
Completed Phase 3 Interventional

Study of Alfimeprase to Rapidly Dissolve Blood Clots in the Leg and Help Prevent the Need for Surgery on Leg Arteries

NCT00115999
View directory record Official record
Conditions
Arterial Occlusive Diseases
Interventions
alfimeprase
Drug
Lead sponsor
ARCA Biopharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 14, 2008 · Synced Jun 10, 2026, 8:29 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Heart and Hands Study II: A Retrospective Data Collection & Analysis Project

NCT02307318
View directory record Official record
Conditions
Thrombosis
Interventions
SoftSeal Hemostatic Pad
Device
Lead sponsor
HealthEast Care System
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 10, 2017 · Synced Jun 10, 2026, 8:29 AM EDT
Recruiting Phase 3 Interventional

REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis

NCT07410117
View directory record Official record
Conditions
Cancer-Associated Thrombosis (CAT)
Interventions
REGN7508, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
3
States / cities
Hialeah, Florida • North Miami Beach, Florida • El Paso, Texas
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Jun 10, 2026, 8:29 AM EDT
Completed Phase 4 Interventional Results available

Pharmacogenomics of Antiplatelet Response - II (PARes-II)

NCT01894555
View directory record Official record
Conditions
Atherothrombosis
Interventions
Aspirin
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
45 Years to 75 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 8, 2017 · Synced Jun 10, 2026, 8:29 AM EDT
Completed Not applicable Interventional

Selective Pulmonary-artery Intervention to Reduce Acute Right-heart tEnsion-II

NCT06576427
View directory record Official record
Conditions
Pulmonary Embolism
Interventions
Vertex Pulmonary Embolectomy System
Device
Lead sponsor
Jupiter Endovascular
Industry
Eligibility
18 Years to 79 Years
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
18
States / cities
Hartford, Connecticut • Pensacola, Florida • Atlanta, Georgia + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced Jun 10, 2026, 8:29 AM EDT
Terminated Phase 3 Interventional

Study of Alfimeprase's Ability to Dissolve Blood Clots in the Leg and Help Prevent the Need for Surgery

NCT00338585
View directory record Official record
Conditions
Arterial Occlusive Diseases
Interventions
alfimeprase
Drug
Lead sponsor
ARCA Biopharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jan 14, 2008 · Synced Jun 10, 2026, 8:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn About How Safe BAY3018250 is and What Happens to it in Healthy Japanese Men and Adult Participants Aged 18 to 55 Years

NCT06562985
View directory record Official record
Conditions
Acute Venous and Arterial Thrombotic and Thromboembolic Events, Healthy Volunteers
Interventions
BAY3018250 Dose 1, Placebo, BAY3018250 Dose 2 infusion, BAY3018250 Dose 2 injection
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Los Alamitos, California
Source: ClinicalTrials.gov public record
Updated Feb 5, 2025 · Synced Jun 10, 2026, 8:29 AM EDT
Suspended Phase 3 Interventional

Veliflapon (DG-031)to Prevent Heart Attacks or Stroke in Patients With a History of Heart Attack or Unstable Angina

NCT00353067
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
veliflapon (DG-031)
Drug
Lead sponsor
deCODE genetics
Industry
Eligibility
35 Years and older
Enrollment
3,450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
11
States / cities
Montgomery, Alabama • Jacksonville, Florida • Melrose Park, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2006 · Synced Jun 10, 2026, 8:29 AM EDT
Withdrawn Phase 4 Interventional

ATHERO: Advanced Technology Halting Early Re-Stenosis and Occlusion

NCT00407940
View directory record Official record
Conditions
Arterial Occlusive Disease, Intermittent Claudication
Interventions
Lower extremity Atherectomy and Cryoplasty
Device
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 12, 2019 · Synced Jun 10, 2026, 8:29 AM EDT
Completed Phase 1 Interventional

A Dose Escalation and Safety Study of Plasmin (Human) In Acute Lower Extremity Native Artery or Bypass Graft Occlusion

NCT00418483
View directory record Official record
Conditions
Arterial Occlusive Diseases
Interventions
Plasmin (Human) 25 mg, Plasmin (Human) 50 mg, Plasmin (Human) 75 mg, Plasmin (Human) 100 mg, Plasmin (Human) 125 mg, Plasmin (Human) 150 mg, Plasmin (Human) 175 mg
Biological
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 30, 2016 · Synced Jun 10, 2026, 8:29 AM EDT
Completed Phase 4 Interventional Results available

Prevention of Arteriovenous Thrombotic Events in Critically-Ill COVID-19 Patients Trial

NCT04409834
View directory record Official record
Conditions
COVID-19, Venous Thromboembolism, Arterial Thrombosis
Interventions
Unfractionated Heparin IV, Enoxaparin 1 mg/kg, Clopidogrel, Unfractionated heparin SC, Enoxaparin 40 mg SC
Drug
Lead sponsor
The TIMI Study Group
Other
Eligibility
18 Years and older
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 18, 2024 · Synced Jun 10, 2026, 8:29 AM EDT
Completed Phase 4 Interventional Results available

Ticagrelor Versus Clopidogrel in Type 2 Diabetic Patients

NCT01823510
View directory record Official record
Conditions
Type-2 Diabetes Mellitus, Coronary Artery Disease
Interventions
Ticagrelor + Aspirin, Clopidogrel + Aspirin
Drug
Lead sponsor
Juan J Badimon
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 7, 2017 · Synced Jun 10, 2026, 8:29 AM EDT
Completed Phase 3 Interventional Results available

Long Term Safety of Clopidogrel in Neonates/Infants With Systemic to Pulmonary Artery Shunt Palliation

NCT00833703
View directory record Official record
Conditions
Heart Defects, Congenital
Interventions
Clopidogrel, placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
12 Months and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 21, 2011 · Synced Jun 10, 2026, 8:29 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Inflammation, Viral Replication, and Atherosclerosis in Treated HIV Infection

NCT01519141
View directory record Official record
Conditions
Atherosclerosis
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Enrollment
579 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2021
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Jun 10, 2026, 8:29 AM EDT
Withdrawn No phase listed Observational

Impact of Anti-platelet Drug Exposure on Platelet mRNA Splicing in Healthy Subjects

NCT04088123
View directory record Official record
Conditions
Thrombosis; Artery
Interventions
Ticagrelor Oral Tablet [Brilinta]
Drug
Lead sponsor
George Washington University
Other
Eligibility
18 Years to 70 Years
Timeline
2020
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 27, 2021 · Synced Jun 10, 2026, 8:29 AM EDT
Completed Phase 4 Interventional

Safety of Low Dose IV Contrast CT Scanning in Chronic Kidney Disease

NCT02476526
View directory record Official record
Conditions
Chronic Kidney Disease, Pulmonary Embolism, Renal Artery Stenosis, Pulmonary Cancer
Interventions
Low Volume iso-osmolar non-ionic radio contrast medium, Acetylcysteine Inhalation, Sodium Bicarbonate Solution, 64-MDCT Scanning
Drug · Procedure
Lead sponsor
VA Greater Los Angeles Healthcare System
Federal
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 27, 2017 · Synced Jun 10, 2026, 8:29 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Apixaban Versus Warfarin for the Management of Post-operative Atrial Fibrillation

NCT02889562
View directory record Official record
Conditions
Coronary Artery Bypass Grafting, Postoperative Atrial Fibrilation, Stroke, Systemic Embolism, Deep Venous Thrombosis
Interventions
Apixaban, Warfarin
Drug
Lead sponsor
Sanford Health
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Jan 21, 2021 · Synced Jun 10, 2026, 8:29 AM EDT